We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Thrombotargets and Specs Achieve Milestone in Drug Discovery Collaboration and Begin a new Anticoagulant Program

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Since Specs and Thrombotargets Corp announced their drug discovery collaboration agreement, in 2006, Thrombotargets has carried out the HTS of specific library provided by Specs with its BioPlatformScreen ™ technology.

Thrombotargets has been able to identify some new anticoagulant small molecules.

The discovered hits exert an important potency and its therapeutical window is much wider than those of Heparins, Low Molecular Weight Heparins (LMWH) and other standard treatments.

“We are very excited and feel very optimistic regarding this success in our collaboration with Specs. In addition, these new hits will balance our present peptide-based and antibody-based anticoagulant programs” said Dr. Javier Pedreño, President and CEO of Thrombotargets Corp.

“We are confident that the combined power of our high quality screening compounds library and Thrombotargets’  BioPlatformScreen™ Technology will generate even more new projects“ said Johan Tijhuis, Specs’ CEO.

Thrombotargets and Specs have decided to continue Drug Discovery collaboration to take advantage of their respective technologies and know-how, in the Hit to Lead and Lead Optimization process.